Status:
TERMINATED
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Lead Sponsor:
Hopital A Michallon
Collaborating Sponsors:
University Hospital, Grenoble
Central Hospital, Nancy, France
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients. The correlation between ribavirin plasma...
Detailed Description
1. Background and rational The serum concentrationS of ribavirin commonly range from 1 to 5 in patients during the combination treatment " interferon+ribavirin " (Larrat et al. 2003). However, the bio...
Eligibility Criteria
Inclusion
- Patients with chronic hepatitis C related to genotype 1 or 4 virus and for which a combination therapy is needed will be eligible.
Exclusion
- Patients with co-infection (either VHB or VIH) or with concomitant treatments expected to interact with the endpoints (hemoglobin, viral load, serum ribavirin) will be excluded.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00209755
Start Date
October 1 2003
End Date
July 1 2004
Last Update
September 21 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
university hospital ; HGE dpt
Grenoble, France, 38043